Back to Search Start Over

Core Proteomics and Immunoinformatic Approaches to Design a Multiepitope Reverse Vaccine Candidate against Chagas Disease

Authors :
Sk Injamamul Islam
Saloa Sanjida
Sheikh Sunzid Ahmed
Mazen Almehmadi
Mamdouh Allahyani
Abdulelah Aljuaid
Ahad Amer Alsaiari
Mustafa Halawi
Source :
Vaccines, Vol 10, Iss 10, p 1669 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Chagas disease is a tropical ailment indigenous to South America and caused by the protozoan parasite Trypanosoma cruzi, which has serious health consequences globally. Insect vectors transmit the parasite and, due to the lack of vaccine availability and limited treatment options, we implemented an integrated core proteomics analysis to design a reverse vaccine candidate based on immune epitopes for disease control. Firstly, T. cruzi core proteomics was used to identify immunodominant epitopes. Therefore, we designed the vaccine sequence to be non-allergic, antigenic, immunogenic, and to have better solubility. After predicting the tertiary structure, docking and molecular dynamics simulation (MDS) were performed with TLR4, MHC-I, and MHC-II receptors to discover the binding affinities. The final vaccine design demonstrated significant hydrogen bond interactions upon docking with TLR4, MHC-I, and MHC-II receptors. This indicated the efficacy of the vaccine candidate. A server-based immune simulation approach was generated to predict the efficacy. Significant structural compactness and binding stability were found based on MDS. Finally, by optimizing codons on Escherichia coli K12, a high GC content and CAI value were obtained, which were then incorporated into the cloning vector pET2+ (a). Thus, the developed vaccine sequence may be a viable therapy option for Chagas disease.

Details

Language :
English
ISSN :
2076393X
Volume :
10
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.b326da7040c745bc8ac3f7e556eb494e
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines10101669